Analysts expect that BioTelemetry Inc (NASDAQ:BEAT) will report $0.39 earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Three analysts have provided estimates for BioTelemetry’s earnings. The lowest EPS estimate is $0.34 and the highest is $0.43. BioTelemetry reported earnings of $0.32 per share during the same quarter last year, which would indicate a positive year over year growth rate of 21.9%. The business is expected to announce its next quarterly earnings report on Thursday, February 28th.
According to Zacks, analysts expect that BioTelemetry will report full-year earnings of $1.72 per share for the current year, with EPS estimates ranging from $1.50 to $1.82. For the next financial year, analysts forecast that the company will post earnings of $1.72 per share, with EPS estimates ranging from $1.59 to $1.80. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for BioTelemetry.
BioTelemetry (NASDAQ:BEAT) last posted its quarterly earnings data on Tuesday, October 30th. The medical research company reported $0.53 earnings per share for the quarter, topping the consensus estimate of $0.32 by $0.21. The company had revenue of $100.00 million during the quarter, compared to analysts’ expectations of $97.89 million. BioTelemetry had a return on equity of 22.56% and a net margin of 4.34%. BioTelemetry’s revenue for the quarter was up 23.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.16 earnings per share.
Several analysts recently issued reports on BEAT shares. SunTrust Banks upped their target price on BioTelemetry to $67.00 and gave the stock a “buy” rating in a report on Friday, August 31st. Lake Street Capital upped their target price on BioTelemetry from $50.00 to $90.00 and gave the stock a “buy” rating in a report on Thursday, July 26th. BidaskClub lowered BioTelemetry from a “strong-buy” rating to a “buy” rating in a report on Thursday, October 4th. Finally, Raymond James dropped their target price on BioTelemetry from $66.00 to $64.00 and set an “outperform” rating on the stock in a report on Wednesday, October 31st. Eight equities research analysts have rated the stock with a buy rating, BioTelemetry has a consensus rating of “Buy” and a consensus target price of $61.17.
In other BioTelemetry news, Director Kirk E. Gorman sold 625 shares of BioTelemetry stock in a transaction dated Monday, October 1st. The stock was sold at an average price of $65.07, for a total transaction of $40,668.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Fred Broadway sold 90,113 shares of BioTelemetry stock in a transaction dated Friday, September 28th. The shares were sold at an average price of $65.00, for a total value of $5,857,345.00. The disclosure for this sale can be found here. Insiders have sold a total of 122,363 shares of company stock valued at $7,810,901 in the last quarter. Company insiders own 8.30% of the company’s stock.
A number of hedge funds have recently added to or reduced their stakes in the business. LPL Financial LLC boosted its holdings in BioTelemetry by 15.1% in the first quarter. LPL Financial LLC now owns 20,884 shares of the medical research company’s stock worth $648,000 after purchasing an additional 2,739 shares during the last quarter. Castleark Management LLC bought a new position in shares of BioTelemetry during the 2nd quarter worth approximately $13,712,000. Swiss National Bank increased its stake in BioTelemetry by 5.6% during the 2nd quarter. Swiss National Bank now owns 56,600 shares of the medical research company’s stock valued at $2,547,000 after purchasing an additional 3,000 shares in the last quarter. OppenheimerFunds Inc. acquired a new position in BioTelemetry during the 2nd quarter valued at approximately $205,000. Finally, Legal & General Group Plc increased its stake in BioTelemetry by 2.9% during the 1st quarter. Legal & General Group Plc now owns 57,741 shares of the medical research company’s stock valued at $1,778,000 after purchasing an additional 1,653 shares in the last quarter. Institutional investors and hedge funds own 92.33% of the company’s stock.
BEAT opened at $64.30 on Friday. BioTelemetry has a 52-week low of $23.30 and a 52-week high of $66.29. The stock has a market cap of $2.14 billion, a P/E ratio of 66.29, a P/E/G ratio of 3.73 and a beta of 1.58. The company has a debt-to-equity ratio of 0.66, a quick ratio of 2.50 and a current ratio of 2.68.
BioTelemetry, Inc, a mobile and wireless medical technology company, provides cardiac and mobile blood glucose monitoring (BGM), centralized medical imaging, and original equipment manufacturing services for the healthcare and clinical research industries. It operates in three segments: Healthcare, Research, and Technology.
Read More: Short Selling – Explanation For Shorting Stocks
Get a free copy of the Zacks research report on BioTelemetry (BEAT)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.